Neumora

2023年7月28日

收到一封電子郵件在發布新文章時請提供您的電子郵件地址來接收電子郵件當張貼新文章。請稍後再試。如果你繼續這個問題請聯係customerservice@slackinc.com。回到Healio藥物顯著降低抑鬱和快感缺乏症狀和有意義的。單一療法治療重度抑鬱症,設置進入三期臨床項目,與一種新藥應用程序預期在2025年,根據一份新聞稿。階段3 programcalled KOASTALwill測試navacaprant的安全性和有效性從今年開始,Neumora。之前的2期臨床試驗參與者與moderatetosevere重度抑鬱症症狀包括快感缺乏。“這些症狀是最具挑戰性的治療,造成重大的負麵影響病人的生活質量,”保羅•l . Berns Neumora的聯合創始人兼執行主席,在發布會上說。“抑鬱病人應該得到更好的治療方案,我們正在與緊急應對嚴重的未滿足的醫療需求,仍然存在。“Navacaprant是口服單藥治療對重度抑鬱症的劑量80毫克每日一次。這是一個小說,高度選擇性κ阿片受體拮抗劑,是一個“已知良好途徑調解則說,“釋放。 The phase 3 KOASTAL program consists of four studies. Navacaprant’s efficacy will be tested in three randomized, placebo-controlled, double-blind studies across the U.S., Canada, Latin America, Europe and Asia Pacific region. Following those studies, participants can enroll in an open-label extension study, KOASTAL-LT, evaluating the drug’s long-term safety. Neumora expects the studies to support a new drug application for monotherapy in 2025. Treatment-emergent adverse events affected 35.3% of people in the navacaprant group. Most events were mild to moderate, and none were severe. There was no association with sexual dysfunction, weight gain or suicidal behavior. Roger S. McIntyre, MD, FRCPC, professor of psychiatry and pharmacology at the University of Toronto, said in the release that phase 2 results were “compelling” and that he is “excited that these benefits will be further studied in the global phase 3 KOASTAL program.” Read more about